AU2018225566B2 - Methods of treating cancer with farnesyltransferase inhibitors - Google Patents
Methods of treating cancer with farnesyltransferase inhibitors Download PDFInfo
- Publication number
- AU2018225566B2 AU2018225566B2 AU2018225566A AU2018225566A AU2018225566B2 AU 2018225566 B2 AU2018225566 B2 AU 2018225566B2 AU 2018225566 A AU2018225566 A AU 2018225566A AU 2018225566 A AU2018225566 A AU 2018225566A AU 2018225566 B2 AU2018225566 B2 AU 2018225566B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- sample
- fti
- cxcl12
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019203548A AU2019203548C1 (en) | 2017-02-21 | 2019-05-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| AU2019246922A AU2019246922A1 (en) | 2017-02-21 | 2019-10-11 | Methods of treating cancer with farnesyltransferase inhibitors |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461602P | 2017-02-21 | 2017-02-21 | |
| US62/461,602 | 2017-02-21 | ||
| US201762507749P | 2017-05-17 | 2017-05-17 | |
| US62/507,749 | 2017-05-17 | ||
| US201762519819P | 2017-06-14 | 2017-06-14 | |
| US62/519,819 | 2017-06-14 | ||
| US15/820,157 US9956215B1 (en) | 2017-02-21 | 2017-11-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| US15/820,012 US10137121B2 (en) | 2017-02-21 | 2017-11-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| US15/820,157 | 2017-11-21 | ||
| US15/820,012 | 2017-11-21 | ||
| US201762596653P | 2017-12-08 | 2017-12-08 | |
| US62/596,653 | 2017-12-08 | ||
| PCT/US2018/018989 WO2018156609A1 (en) | 2017-02-21 | 2018-02-21 | Methods of treating cancer with farnesyltransferase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019203548A Division AU2019203548C1 (en) | 2017-02-21 | 2019-05-21 | Methods of treating cancer with farnesyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018225566A1 AU2018225566A1 (en) | 2018-11-08 |
| AU2018225566B2 true AU2018225566B2 (en) | 2019-11-07 |
Family
ID=63253363
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018225566A Active AU2018225566B2 (en) | 2017-02-21 | 2018-02-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| AU2019203548A Active AU2019203548C1 (en) | 2017-02-21 | 2019-05-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| AU2019246922A Abandoned AU2019246922A1 (en) | 2017-02-21 | 2019-10-11 | Methods of treating cancer with farnesyltransferase inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019203548A Active AU2019203548C1 (en) | 2017-02-21 | 2019-05-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| AU2019246922A Abandoned AU2019246922A1 (en) | 2017-02-21 | 2019-10-11 | Methods of treating cancer with farnesyltransferase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP3432883B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7289795B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20200090982A (cg-RX-API-DMAC7.html) |
| CN (4) | CN109999037A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018225566B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019017375A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3053795A1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2927228T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL268722A (cg-RX-API-DMAC7.html) |
| MX (2) | MX394077B (cg-RX-API-DMAC7.html) |
| PH (1) | PH12019501918A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201907594TA (cg-RX-API-DMAC7.html) |
| TW (3) | TWI738314B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018156609A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10137121B2 (en) | 2017-02-21 | 2018-11-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| CA3071854A1 (en) * | 2017-08-07 | 2019-02-14 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| US20220143006A1 (en) * | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| WO2025224720A1 (en) * | 2024-04-24 | 2025-10-30 | Biolinerx Ltd. | Methods of selecting treatment regimen against solid tumors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017184968A1 (en) * | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
| US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
| IE72468B1 (en) | 1987-07-31 | 1997-04-09 | Univ Leland Stanford Junior | Selective amplification of target polynucleotide sequences |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| ZA918965B (en) | 1990-11-13 | 1992-08-26 | Siska Diagnostics Inc | Nucleic acid amplification by two-enzyme,self-sustained sequence replication |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| WO1993018186A1 (en) | 1992-03-04 | 1993-09-16 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| WO1998028303A1 (en) | 1996-12-20 | 1998-07-02 | Tovarischestvo S Ogranichennoi Otvetstvennostju 'tabifarm' | METHOD AND DEVICE FOR PRODUCTION OF LYOPHILIZED HYDROCHLORIDE-1β,10β-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-OLIDE |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| NZ505651A (en) | 1998-01-16 | 2003-08-29 | Takeda Chemical Industries Ltd | Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer |
| PT1060619E (pt) | 1998-03-05 | 2002-11-29 | Formula One Administration Ltd | Sistema de comunicacao de dados |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| ID26987A (id) | 1998-07-06 | 2001-02-22 | Janssen Pharmaceutica Nv | Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo |
| CA2341739C (en) | 1998-08-27 | 2005-07-12 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| KR20010072991A (ko) | 1998-08-27 | 2001-07-31 | 실버스타인 아써 에이. | 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체 |
| US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU3074001A (en) | 1999-12-09 | 2001-06-18 | Advanced Research And Technology Institute, Inc. | Fluorescent in situ rt-pcr |
| JP2003523381A (ja) | 2000-02-24 | 2003-08-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 投与レジメン |
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| ATE475408T1 (de) * | 2005-10-14 | 2010-08-15 | Janssen Pharmaceutica Nv | Formulierungen von tipifarnib zur intravenösen verabreichung |
| JP2012507555A (ja) * | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗cs1抗体の使用 |
| EP2391211A4 (en) * | 2009-01-30 | 2012-11-07 | Genzyme Corp | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER |
| AU2011282614B2 (en) * | 2010-07-28 | 2015-11-26 | Janssen Pharmaceutica Nv | Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors |
| EP2476441A1 (en) * | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| HUE043001T2 (hu) * | 2011-11-09 | 2019-07-29 | Bristol Myers Squibb Co | Hematológiai malignómák kezelése anti-CXCR4 antitesttel |
| CN103787907B (zh) * | 2014-02-17 | 2015-05-27 | 华东理工大学 | 作为法尼基转移酶抑制剂的苯胺类化合物及其用途 |
-
2018
- 2018-02-21 WO PCT/US2018/018989 patent/WO2018156609A1/en not_active Ceased
- 2018-02-21 CA CA3053795A patent/CA3053795A1/en active Pending
- 2018-02-21 CN CN201910346412.3A patent/CN109999037A/zh active Pending
- 2018-02-21 AU AU2018225566A patent/AU2018225566B2/en active Active
- 2018-02-21 CN CN202210399515.8A patent/CN114796218A/zh active Pending
- 2018-02-21 EP EP18708563.4A patent/EP3432883B1/en active Active
- 2018-02-21 ES ES19172562T patent/ES2927228T3/es active Active
- 2018-02-21 MX MX2019009821A patent/MX394077B/es unknown
- 2018-02-21 EP EP19172562.1A patent/EP3542800B1/en active Active
- 2018-02-21 EP EP22176008.5A patent/EP4119142A1/en not_active Withdrawn
- 2018-02-21 JP JP2019566054A patent/JP7289795B2/ja active Active
- 2018-02-21 BR BR112019017375-7A patent/BR112019017375A2/pt not_active Application Discontinuation
- 2018-02-21 TW TW109114622A patent/TWI738314B/zh active
- 2018-02-21 SG SG11201907594TA patent/SG11201907594TA/en unknown
- 2018-02-21 CN CN201880002051.4A patent/CN109475550A/zh active Pending
- 2018-02-21 TW TW108113624A patent/TWI693074B/zh not_active IP Right Cessation
- 2018-02-21 KR KR1020207021424A patent/KR20200090982A/ko not_active Ceased
- 2018-02-21 ES ES18708563T patent/ES2892157T3/es active Active
- 2018-02-21 KR KR1020197020747A patent/KR102138904B1/ko not_active Expired - Fee Related
- 2018-02-21 TW TW107105861A patent/TWI663974B/zh not_active IP Right Cessation
- 2018-02-21 CN CN202210399518.1A patent/CN114712354A/zh active Pending
- 2018-02-21 KR KR1020187032097A patent/KR102003179B1/ko not_active Expired - Fee Related
-
2019
- 2019-05-21 AU AU2019203548A patent/AU2019203548C1/en active Active
- 2019-08-15 IL IL26872219A patent/IL268722A/en unknown
- 2019-08-16 MX MX2022008843A patent/MX2022008843A/es unknown
- 2019-08-19 PH PH12019501918A patent/PH12019501918A1/en unknown
- 2019-10-11 AU AU2019246922A patent/AU2019246922A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017184968A1 (en) * | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| WITZIG, T et al. "Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas". BLOOD, 2011. Vol.118(18): pages 4882-9 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10980793B2 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| AU2019203548B2 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| US20220142983A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| US20190119758A1 (en) | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors | |
| US11291663B2 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| US10806730B2 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| US20170326133A1 (en) | Methods of treating myelodysplastic syndrome with farnesyltransferase inhibitors | |
| US20220168296A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| HK40006709B (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| HK40006709A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| HK1262842B (en) | Methods of treating cancer with farnesyltransferase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |